Sunday, March 20, 2016

BRIEF-Amgen -Positive Top Line results from Phase 3 study evaluating Romosozumab in men with Osteoporosis

* Amgen And Ucb Announce Positive Top Line results from

Phase 3 study evaluating Romosozumab in men with Osteoporosis

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)